Please check this page for news updates
And to follow our progress.
AliquantumRx Inc., a Johns Hopkins FastForward company supported by Maryland Technology Development Corporation (TEDCO) is
David Sullivan, MD, Johns Hopkins University receives a 3 year CDMRP grant entitled “A Pharmacokinetic
Patent Cooperation Treaty Application Salts and Polymorphs of Cethromycin for the Treatment of Disease PCT/US2020/062882
Clinical Trial Success Story: David Sullivan, MD, JHU-led Team Study Finds Convalescent Plasma Can Be
Patent Cooperation Treaty Application Salts and Polymorphs of Cethromycin for the Treatment of Disease is
Global Patent Group, LLC files a Patent cooperation treaty (PCT) application PCT/US20/62882 on December 2,
AliquantumRx Inc. announces a phase III MII funding for a project entitled “Development of Cethromycin
AliquantumRx Inc. announces the filing of a provisional patent application No. 62/942,508 entitled “Salts and
AliquantumRx Inc. announces that it has attracted an initial capital investment of up to $500,000
AliquantumRx Inc. has entered into a licensing agreement with JHTV for all of their IP
Johns Hopkins Technology Ventures files for nationalization of PCT/US15/46665.
Quantum-Biosciences LLC, a start-up company formed with the mission of development and commercialization of Cethromycin/QB101
David Sullivan, MD, professor at Johns Hopkins Bloomberg School of Public Health has been awarded
David Sullivan, MD, professor at Johns Hopkins Bloomberg School of Public Health, was awarded a
Patent cooperation treaty (PCT) application PCT/US15/46665 was filed on 25 August 2015 by Johns Hopkins
Quantum-Biosciences, LLC, a new bio-tech start up launches this month to meet urgent need for
David Sullivan, MD, a professor of molecular microbiology and immunology at the Johns Hopkins Malaria
Provisional patent application No. 62/411404 was filed on 25 August 2014 by Johns Hopkins Technology
From JHU’s press release: David Sullivan, MD, an associate professor with the Bloomberg School’s Department